Insider Selling: Monopar Therapeutics (NASDAQ:MNPR) Director Sells $206,012.66 in Stock

Monopar Therapeutics Inc. (NASDAQ:MNPR) Director Kim Tsuchimoto sold 2,891 shares of the company’s stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $71.26, for a total value of $206,012.66. Following the completion of the transaction, the director owned 1,199 shares in the company, valued at $85,440.74. This represents a 70.68% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Monopar Therapeutics Stock Performance

Shares of NASDAQ MNPR traded up $2.92 during mid-day trading on Wednesday, reaching $72.81. The company had a trading volume of 189,611 shares, compared to its average volume of 143,006. The company has a market capitalization of $488.56 million, a price-to-earnings ratio of -33.55 and a beta of 1.62. The stock has a fifty day moving average of $88.66 and a two-hundred day moving average of $77.40. Monopar Therapeutics Inc. has a 12-month low of $50.07 and a 12-month high of $124.82.

Monopar Therapeutics (NASDAQ:MNPR) last released its earnings results on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.02. Sell-side analysts forecast that Monopar Therapeutics Inc. will post -2.98 earnings per share for the current fiscal year.

Institutional Trading of Monopar Therapeutics

A number of hedge funds have recently bought and sold shares of MNPR. Siren L.L.C. grew its holdings in shares of Monopar Therapeutics by 27.2% during the 1st quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock worth $14,800,000 after purchasing an additional 57,820 shares in the last quarter. ADAR1 Capital Management LLC boosted its stake in shares of Monopar Therapeutics by 13.0% in the 1st quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock valued at $14,480,000 after purchasing an additional 30,370 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Monopar Therapeutics by 21.2% in the first quarter. Bank of New York Mellon Corp now owns 78,618 shares of the company’s stock valued at $4,307,000 after buying an additional 13,761 shares in the last quarter. Walleye Capital LLC acquired a new stake in Monopar Therapeutics during the 1st quarter valued at $3,458,000. Finally, Bank of America Corp DE increased its stake in shares of Monopar Therapeutics by 838.2% in the first quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock valued at $3,271,000 after buying an additional 53,336 shares in the last quarter. 1.83% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have weighed in on MNPR shares. Morgan Stanley reaffirmed an “overweight” rating and issued a $130.00 target price on shares of Monopar Therapeutics in a research report on Monday, August 17th. Barclays reaffirmed an “overweight” rating and set a $145.00 price objective (up from $128.00) on shares of Monopar Therapeutics in a research report on Friday, September 11th. Cantor Fitzgerald cut shares of Monopar Therapeutics from an “overweight” rating to a “neutral” rating and lifted their target price for the company from $109.00 to $119.00 in a research note on Thursday, August 13th. Wall Street Zen downgraded shares of Monopar Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, October 10th. Finally, HC Wainwright lifted their price objective on shares of Monopar Therapeutics from $105.00 to $125.00 and gave the company a “buy” rating in a research note on Wednesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $122.00.

About Monopar Therapeutics

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing investigational therapies for cancer. The company’s research programs are centered on radiopharmaceuticals and oncology treatments intended to improve the diagnosis and treatment of serious malignancies.

Monopar’s pipeline includes MNPR-101-Zr, a zirconium-89-labeled antibody fragment being developed as a positron emission tomography imaging agent targeting the urokinase plasminogen activator receptor, or uPAR.